Antispasmodics Drugs Global Market Report 2024

Description

“Antispasmodics Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antispasmodics drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antispasmodics drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antispasmodics drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug: Dicyclomine Hydrochloride; Loperamide Hydrochloride; Other Drugs
2) By Indication: Irritable Bowel Syndrome; Stomach Cramps; Other Indications
3) By Route Of Administration: Oral; Parenteral; Other Modes Of Administrations
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Companies Mentioned: Daiichi Sankyo Company Limited; Fresenius Kabi AG; Hikma Pharmaceuticals plc; Johnson & Johnson Services Inc.; Pfizer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Antispasmodic drugs are medications designed to treat, prevent, or decrease the frequency of muscular spasms, especially those involving smooth muscle, such as those occurring in the walls of the gastrointestinal tract. These drugs function by slowing down the normal movements of the gut and inducing relaxation in the muscles of the stomach and intestines.

Key drugs in the category of antispasmodics include dicyclomine hydrochloride, loperamide hydrochloride, and others. Dicyclomine is an anticholinergic medication that reduces spasms in the gastrointestinal muscles by inhibiting the activity of a natural chemical in the body. Indications for the use of antispasmodic drugs include conditions such as irritable bowel syndrome, stomach cramps, and others. These medications can be administered through oral, parenteral, and other modes. Distribution channels for antispasmodic drugs include hospital pharmacies, online pharmacies, and retail pharmacies, with end-users ranging from hospitals and homecare settings to specialty clinics and others.

The antispasmodics drugs market research report is one of a series of new reports from The Business Research Company that provides antispasmodics drugs market statistics, including antispasmodics drugs industry global market size, regional shares, competitors with antispasmodics drugs market share, detailed antispasmodics drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the antispasmodics drugs industry. This antispasmodic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antispasmodics drugs market size has grown strongly in recent years. It will grow from $12.69 billion in 2023 to $13.92 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth observed during the historical period in the field of antispasmodic drugs can be attributed to several factors. These include the increasing prevalence of conditions associated with spasms, advancements in medical research leading to better understanding and treatment options, a growing aging population with associated healthcare needs, changes in lifestyles impacting health conditions, and improvements in diagnostic capabilities. These factors collectively contributed to the demand and development of antispasmodic drugs during the historic period.

The antispasmodics drugs market size is expected to see strong growth in the next few years. It will grow to $20.04 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth in the forecast period in the field of antispasmodic drugs can be attributed to several factors. These include the increasing expenditure on healthcare, the trend towards personalized medicine, global population growth leading to higher healthcare demands, the emergence of new markets for pharmaceuticals, and ongoing clinical trials and research in the field. Major trends expected in the forecast period encompass the expansion of indications for antispasmodics, ongoing development of healthcare infrastructure, advancements in drug development processes, increasing awareness and diagnosis of spasmodic conditions, and a growing preference for non-invasive treatment options. These trends collectively contribute to the continued evolution and growth of the antispasmodic drugs market.

The anticipated rise in the elderly population stands as a driving force behind the growth of the antispasmodic drug market. Individuals aged 65 and above, often grappling with various physical and psychological health challenges, find relief in antispasmodic drugs to manage symptoms linked to conditions causing muscle spasms or cramping. These drugs also prove beneficial for ailments such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. In October 2022, the World Health Organization (WHO) projected a substantial increase in the global population aged 60 and above, expected to reach 1.4 billion by 2030 and double to 2.1 billion by 2050. This demographic shift, including a significant rise in those aged 80 or older, estimated to reach 426 million by 2050, underscores the impetus driving the antispasmodic drug market linked to an expanding elderly populace.

The burgeoning prevalence of irritable bowel syndrome (IBS) is poised to fuel the growth of the antispasmodic drugs market. IBS, a prevalent digestive disorder impacting the colon and causing discomfort and disruptions in digestive functionality, spurs the use of antispasmodics drugs. These medications target and alleviate muscle spasms and cramps within the gastrointestinal tract, providing relief from abdominal pain and discomfort associated with IBS. For example, statistics from The Public Health Agency of Canada in July 2021 revealed approximately 260,000 Canadians affected by Inflammatory Bowel Disease (IBD), commonly identified in adults in their twenties and older teens. This escalation in the prevalence of IBS underscores the driving force behind the expansion of the antispasmodic drugs market, addressing the growing need for effective remedies catering to digestive health.

Innovative product developments emerge as a pivotal trend fueling the ascent of the antispasmodic drugs market. Key players in this domain prioritize pioneering solutions to fortify their market positions. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, unveiled IBSRELA, an NHE-3 inhibitor tailored for individuals grappling with irritable bowel syndrome with constipation (IBS-C). This product represents a breakthrough therapeutic option boasting a novel mode of action, yielding significant efficacy in addressing constipation and assorted abdominal symptoms prevalent in IBS-C patients, as substantiated by Phase 3 clinical studies. This innovative approach underscores the market's trend towards developing impactful solutions catering to specific conditions within the antispasmodic drugs segment.

Prominent entities within the antispasmodics drugs market are unveiling new products as part of their strategy to fortify their market presence. For example, in January 2023, Lupin Limited, an India-based pharmaceutical company, introduced Fesoterodine Fumarate, an FDA-approved generic antispasmodic drug. This medication is specifically designed to address certain bladder issues such as overactive bladder and neurogenic detrusor overactivity. Belonging to the antispasmodic drug class, Fesoterodine Fumarate functions by relaxing the muscles in the bladder. It is available in extended-release tablet form, representing a new addition to Lupin Limited's repertoire in addressing bladder-related ailments.

In October 2022, Silo Wellness Inc., a US-based company specializing in psychedelic therapy, concluded the acquisition of Dyscovry Science Ltd. for an undisclosed amount. This strategic acquisition enables Silo Wellness to consolidate its presence in the psychedelic business landscape. Dyscovry Science Ltd., a Canada-based biotechnology firm, specializes in biosynthetic production of psilocybin and its derivatives for treating irritable bowel syndrome. By incorporating Dyscovry Science Ltd., Silo Wellness aims to encompass both facets of the psychedelic industry, augmenting its capabilities in research and biosynthetic development for innovative treatment solutions.

Major companies operating in the antispasmodics drugs market report are Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd. .

North America was the largest region in the antispasmodics drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antispasmodics drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antispasmodics drugs market consists of sales of natural alkaloids such as atropine, belladonna, hyoscyamine, scopolamine, and related drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r10735

1. Executive Summary

2. Antispasmodics Drugs Market Characteristics

3. Antispasmodics Drugs Market Trends And Strategies

4. Antispasmodics Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Antispasmodics Drugs Market Size and Growth

5.1. Global Antispasmodics Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Antispasmodics Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Antispasmodics Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antispasmodics Drugs Market Segmentation

6.1. Global Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Dicyclomine Hydrochloride
Loperamide Hydrochloride
Other Drugs
6.2. Global Antispasmodics Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Irritable Bowel Syndrome
Stomach Cramps
Other Indications
6.3. Global Antispasmodics Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
Other Modes Of Administrations
6.4. Global Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmnacy
6.5. Global Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users

7. Antispasmodics Drugs Market Regional And Country Analysis

7.1. Global Antispasmodics Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Antispasmodics Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antispasmodics Drugs Market

8.1. Asia-Pacific Antispasmodics Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antispasmodics Drugs Market

9.1. China Antispasmodics Drugs Market Overview
9.2. China Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antispasmodics Drugs Market

10.1. India Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antispasmodics Drugs Market

11.1. Japan Antispasmodics Drugs Market Overview
11.2. Japan Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antispasmodics Drugs Market

12.1. Australia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antispasmodics Drugs Market

13.1. Indonesia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antispasmodics Drugs Market

14.1. South Korea Antispasmodics Drugs Market Overview
14.2. South Korea Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antispasmodics Drugs Market

15.1. Western Europe Antispasmodics Drugs Market Overview
15.2. Western Europe Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antispasmodics Drugs Market

16.1. UK Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antispasmodics Drugs Market

17.1. Germany Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antispasmodics Drugs Market

18.1. France Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antispasmodics Drugs Market

19.1. Italy Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antispasmodics Drugs Market

20.1. Spain Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antispasmodics Drugs Market

21.1. Eastern Europe Antispasmodics Drugs Market Overview
21.2. Eastern Europe Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antispasmodics Drugs Market

22.1. Russia Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antispasmodics Drugs Market

23.1. North America Antispasmodics Drugs Market Overview
23.2. North America Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antispasmodics Drugs Market

24.1. USA Antispasmodics Drugs Market Overview
24.2. USA Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antispasmodics Drugs Market

25.1. Canada Antispasmodics Drugs Market Overview
25.2. Canada Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antispasmodics Drugs Market

26.1. South America Antispasmodics Drugs Market Overview
26.2. South America Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antispasmodics Drugs Market

27.1. Brazil Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antispasmodics Drugs Market

28.1. Middle East Antispasmodics Drugs Market Overview
28.2. Middle East Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antispasmodics Drugs Market

29.1. Africa Antispasmodics Drugs Market Overview
29.2. Africa Antispasmodics Drugs Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Antispasmodics Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Antispasmodics Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antispasmodics Drugs Market Competitive Landscape And Company Profiles

30.1. Antispasmodics Drugs Market Competitive Landscape
30.2. Antispasmodics Drugs Market Company Profiles
- 30.2.1. Daiichi Sankyo Company Limited
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Fresenius Kabi AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Hikma Pharmaceuticals plc
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Johnson & Johnson Services Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Pfizer Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Antispasmodics Drugs Market Competitive Benchmarking

32. Global Antispasmodics Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Antispasmodics Drugs Market

34. Antispasmodics Drugs Market Future Outlook and Potential Analysis

34.1 Antispasmodics Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Antispasmodics Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Antispasmodics Drugs Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer